Oncolytic adenoviral gene therapy in ovarian cancer: why we are not wasting our time

Young, A.M. and Mcneish, I.A. (2009) Oncolytic adenoviral gene therapy in ovarian cancer: why we are not wasting our time. Future Oncology, 5(3), pp. 339-357. (doi: 10.2217/fon.09.11)

Full text not currently available from Enlighten.

Abstract

Preclinical gene-therapy studies in the past 15 years have repeatedly raised hopes that we were about to enter a brave new era. However, many clinical trials have disappointed. For tumor types with poor response rates to first-line conventional cytotoxic chemotherapy and/or high rates of chemorefractory disease, there remain very few treatment options. In this article we review gene therapy within the context of ovarian cancer. We examine why clinical data have been discouraging and discuss how the lessons learned from earlier trials are being applied to current research.

Item Type:Articles
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:Mcneish, Professor Iain
Authors: Young, A.M., and Mcneish, I.A.
College/School:College of Medical Veterinary and Life Sciences > Institute of Cancer Sciences
Journal Name:Future Oncology
ISSN:1479-6694
ISSN (Online):1744-8301

University Staff: Request a correction | Enlighten Editors: Update this record